Predictive value of NLR,MLR and CAR on the efficacy of ustekinumab in patients with Crohn's disease
- 1Department of Gastroenterology,The First Affiliated Hospital(Yijishan Hospital)of Wannan Medical University,Wuhu,Anhui 241001,China
Abstract
Objective To investigate the levels of neutrophil-to-lymphocyte ratio(NLR),monocyte-to-lymphocyte ratio(MLR),and C-reactive protein-to-albumin ratio(CAR)in patients with Crohn's disease treated with ustekinumab,and to evaluate the predictive value of these three individual indicators and their combination for the efficacy of ustekinumab in the treatment of Crohn's disease patients. Methods A retrospective analysis was performed on medical records of 61 patients with Crohn's disease who were treated with ustekinumab at Yijishan Hospital of Wannan Medical University from January 2021 to December 2025. Based on treatment outcomes,18 patients with loss of response were assigned to group A,and 43 patients with effective response were assigned to group B. NLR,MLR,and CAR were compared between the two groups. Receiver operating characteristic(ROC)curves were constructed to assess the predictive value of NLR,MLR,CAR,and their combination for the efficacy of ustekinumab therapy. Results NLR(2.74±1.43 vs 1.79±0.71,t=2.683,P=0.014),MLR(0.30±0.11 vs 0.23±0.06,t=2.546,P=0.016),and CAR［0.31(0.14,0.51)vs 0.05(0.03,0.08),Z=5.134,P<0.01］in group A were significantly higher than those in group B. ROC curve analysis showed that the area under the curve (AUC)for NLR,MLR,and CAR alone in predicting loss of response to ustekinumab were 0.756,0.753,and 0.918,respectively,while the AUC for the combined indicators was 0.970.Conclusion NLR,MLR,and CAR each has certain predictive value for the therapeutic efficacy of ustekinumab in patients with Crohn's disease. The combination of these indicators yields the highest predictive performance and may facilitate early identification of patients with loss of response to ustekinumab therapy.
Related
- Ustekinumab for Extraintestinal Manifestations in Patients With Inflammatory Bowel Disease: Lessons From the TENOR Real-World Study.
- Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
- The predictive value of machine learning for the response to anti-TNF-α therapy in patients with Crohn’s disease: a systematic review and meta-analysis
- A real-world study of healthcare resource utilization and costs in patients with Crohn's disease and ulcerative colitis initiating ustekinumab treatment via Johnson & Johnson's BIOADVANCE program.
- The Predictive Value of Serum Erythropoietin Levels Measured at Diagnosis in Patients With Myelodysplastic Syndromes
BibTeX
@article{jing2026predictive,
title = {{Predictive value of NLR,MLR and CAR on the efficacy of ustekinumab in patients with Crohn's disease}},
author = {WANG Jing and LI Lin and CHEN Pingbo and HE Chiyi and NIU Xiaoping},
journal = {Zhongguo linchuang yanjiu},
year = {2026},
month = oct,
doi = {10.13429/j.cnki.cjcr.2026.10.018},
url = {https://doi.org/10.13429/j.cnki.cjcr.2026.10.018},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Predictive value of NLR,MLR and CAR on the efficacy of ustekinumab in patients with Crohn's disease
AU - WANG Jing
AU - LI Lin
AU - CHEN Pingbo
AU - HE Chiyi
AU - NIU Xiaoping
PY - 2026
DA - 2026/10/26
JO - Zhongguo linchuang yanjiu
DO - 10.13429/j.cnki.cjcr.2026.10.018
UR - https://doi.org/10.13429/j.cnki.cjcr.2026.10.018
AB - Objective To investigate the levels of neutrophil-to-lymphocyte ratio(NLR),monocyte-to-lymphocyte ratio(MLR),and C-reactive protein-to-albumin ratio(CAR)in patients with Crohn's disease treated with ustekinumab,and to evaluate the predictive value of these three individual indicators and their combination for the efficacy of ustekinumab in the treatment of Crohn's disease patients. Methods A retrospective analysis was performed on medical records of 61 patients with Crohn's disease who were treated with ustekinumab at Yijishan Hospital of Wannan Medical University from January 2021 to December 2025. Based on treatment outcomes,18 patients with loss of response were assigned to group A,and 43 patients with effective response were assigned to group B. NLR,MLR,and CAR were compared between the two groups. Receiver operating characteristic(ROC)curves were constructed to assess the predictive value of NLR,MLR,CAR,and their combination for the efficacy of ustekinumab therapy. Results NLR(2.74±1.43 vs 1.79±0.71,t=2.683,P=0.014),MLR(0.30±0.11 vs 0.23±0.06,t=2.546,P=0.016),and CAR［0.31(0.14,0.51)vs 0.05(0.03,0.08),Z=5.134,P<0.01］in group A were significantly higher than those in group B. ROC curve analysis showed that the area under the curve (AUC)for NLR,MLR,and CAR alone in predicting loss of response to ustekinumab were 0.756,0.753,and 0.918,respectively,while the AUC for the combined indicators was 0.970.Conclusion NLR,MLR,and CAR each has certain predictive value for the therapeutic efficacy of ustekinumab in patients with Crohn's disease. The combination of these indicators yields the highest predictive performance and may facilitate early identification of patients with loss of response to ustekinumab therapy.
SN - 1674-8182
ER -